I17RD_HUMAN
ID I17RD_HUMAN Reviewed; 739 AA.
AC Q8NFM7; Q2NKP7; Q58EZ7; Q6RVF4; Q6UWI5; Q8N113; Q8NFS0; Q9UFA0;
DT 13-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT 20-FEB-2007, sequence version 3.
DT 03-AUG-2022, entry version 155.
DE RecName: Full=Interleukin-17 receptor D;
DE Short=IL-17 receptor D;
DE Short=IL-17RD;
DE AltName: Full=IL17Rhom;
DE AltName: Full=Interleukin-17 receptor-like protein;
DE AltName: Full=Sef homolog;
DE Short=hSef;
DE Flags: Precursor;
GN Name=IL17RD; Synonyms=IL17RLM, SEF; ORFNames=UNQ6115/PRO20026;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), VARIANT MET-255, FUNCTION,
RP AND INTERACTION WITH FGFR1 AND FGFR2.
RX PubMed=12958313; DOI=10.1074/jbc.m306936200;
RA Xiong S.Q., Zhao Q.H., Rong Z., Huang G.R., Huang Y., Chen P.L., Zhang S.,
RA Liu L., Chang Z.J.;
RT "hSef inhibits PC-12 cell differentiation by interfering with Ras-mitogen-
RT activated protein kinase MAPK signaling.";
RL J. Biol. Chem. 278:50273-50282(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), VARIANT MET-255, AND SUBCELLULAR
RP LOCATION.
RC TISSUE=Testis;
RX PubMed=14742870; DOI=10.1073/pnas.0307952100;
RA Preger E., Ziv I., Shabtay A., Sher I., Tsang M., Dawid I.B., Altuvia Y.,
RA Ron D.;
RT "Alternative splicing generates an isoform of the human Sef gene with
RT altered subcellular localization and specificity.";
RL Proc. Natl. Acad. Sci. U.S.A. 101:1229-1234(2004).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-255.
RA Gilbert J.M., Gorman D.M.;
RT "Identification of novel IL-17 related receptors.";
RL Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT MET-255.
RX PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT identify novel human secreted and transmembrane proteins: a bioinformatics
RT assessment.";
RL Genome Res. 13:2265-2270(2003).
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT MET-255.
RC TISSUE=Testis;
RX PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA Wiemann S., Schupp I.;
RT "The full-ORF clone resource of the German cDNA consortium.";
RL BMC Genomics 8:399-399(2007).
RN [6]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND VARIANT MET-255.
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [7]
RP FUNCTION, TISSUE SPECIFICITY, HOMOOLIGOMERIZATION, AND INTERACTION WITH
RP FGFR1.
RX PubMed=12807873; DOI=10.1074/jbc.m305022200;
RA Yang R.-B., Domingos Ng C.K., Wasserman S.M., Koemueves L.G.,
RA Gerritsen M.E., Topper J.N.;
RT "A novel interleukin-17 receptor-like protein identified in human umbilical
RT vein endothelial cells antagonizes basic fibroblast growth factor-induced
RT signaling.";
RL J. Biol. Chem. 278:33232-33238(2003).
RN [8]
RP FUNCTION, INTERACTION WITH MAP2K1/2, AND IDENTIFICATION IN A COMPLEX WITH
RP MAP2K1/2 AND MAPK1/3.
RX PubMed=15239952; DOI=10.1016/j.devcel.2004.05.019;
RA Torii S., Kusakabe M., Yamamoto T., Maekawa M., Nishida E.;
RT "Sef is a spatial regulator for Ras/MAP kinase signaling.";
RL Dev. Cell 7:33-44(2004).
RN [9]
RP VARIANTS HH18 THR-131; ARG-162; SER-306; CYS-379; LEU-468; GLN-577 AND
RP VAL-735, AND CHARACTERIZATION OF VARIANTS HH18 THR-131; ARG-162; SER-306;
RP CYS-379; LEU-468; GLN-577 AND VAL-735.
RX PubMed=23643382; DOI=10.1016/j.ajhg.2013.04.008;
RA Miraoui H., Dwyer A.A., Sykiotis G.P., Plummer L., Chung W., Feng B.,
RA Beenken A., Clarke J., Pers T.H., Dworzynski P., Keefe K., Niedziela M.,
RA Raivio T., Crowley W.F. Jr., Seminara S.B., Quinton R., Hughes V.A.,
RA Kumanov P., Young J., Yialamas M.A., Hall J.E., Van Vliet G.,
RA Chanoine J.P., Rubenstein J., Mohammadi M., Tsai P.S., Sidis Y., Lage K.,
RA Pitteloud N.;
RT "Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in
RT individuals with congenital hypogonadotropic hypogonadism.";
RL Am. J. Hum. Genet. 92:725-743(2013).
CC -!- FUNCTION: Feedback inhibitor of fibroblast growth factor mediated Ras-
CC MAPK signaling and ERK activation (PubMed:12958313, PubMed:12807873).
CC Regulates the nuclear ERK signaling pathway by spatially blocking
CC nuclear translocation of activated ERK without inhibiting cytoplasmic
CC phosphorylation of ERK (PubMed:15239952). Mediates JNK activation and
CC may be involved in apoptosis (By similarity). May inhibit FGF-induced
CC FGFR1 tyrosine phosphorylation (By similarity). Might have a role in
CC the early stages of fate specification of GnRH-secreting neurons (By
CC similarity). Inhibits TGFB-induced epithelial-to-mesenchymal transition
CC in lens epithelial cells (By similarity).
CC {ECO:0000250|UniProtKB:Q8JZL1, ECO:0000269|PubMed:12807873,
CC ECO:0000269|PubMed:12958313, ECO:0000269|PubMed:15239952}.
CC -!- SUBUNIT: Interacts with MAP3K7 (By similarity). Self-associates.
CC Interacts with FGFR1, FGFR2 and phosphorylated MAP2K1 or MAP2K2.
CC Associates with a MAP2K1/2-MAPK1/3 complex. {ECO:0000250,
CC ECO:0000269|PubMed:12807873, ECO:0000269|PubMed:12958313,
CC ECO:0000269|PubMed:15239952}.
CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC {ECO:0000269|PubMed:14742870}; Single-pass type I membrane protein
CC {ECO:0000269|PubMed:14742870}. Cell membrane
CC {ECO:0000269|PubMed:14742870}; Single-pass type I membrane protein
CC {ECO:0000269|PubMed:14742870}. Note=Predominantly associated with the
CC Golgi apparatus and is partially translocated to the plasma membrane
CC upon stimulation.
CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Cytoplasm.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=4;
CC Name=1; Synonyms=hSef-a, IL17RLM-L, Long;
CC IsoId=Q8NFM7-1; Sequence=Displayed;
CC Name=2; Synonyms=IL17RLM-S, Short;
CC IsoId=Q8NFM7-2; Sequence=VSP_015582;
CC Name=3;
CC IsoId=Q8NFM7-3; Sequence=VSP_015583;
CC Name=4; Synonyms=hSef-b;
CC IsoId=Q8NFM7-4; Sequence=VSP_015584;
CC -!- TISSUE SPECIFICITY: Expressed in umbilical vein endothelial cells and
CC in several highly vascularized tissues such as kidney, colon, skeletal
CC muscle, heart and small intestine. Highly expressed in ductal
CC epithelial cells of salivary glands, seminal vesicles and the
CC collecting tubules of the kidney. Isoform 1 is also highly expressed in
CC both fetal and adult brain, pituitary, tonsils, spleen, adenoids, fetal
CC kidney, liver, testes and ovary. Isoform 1 is also expressed at
CC moderate levels in primary aortic endothelial cells and adrenal
CC medulla, and at low levels in adrenal cortex. Isoform 4 is specifically
CC and highly expressed in pituitary, fetal brain and umbilical vein
CC endothelial cells. {ECO:0000269|PubMed:12807873}.
CC -!- DISEASE: Hypogonadotropic hypogonadism 18 with or without anosmia
CC (HH18) [MIM:615267]: A disorder characterized by absent or incomplete
CC sexual maturation by the age of 18 years, in conjunction with low
CC levels of circulating gonadotropins and testosterone and no other
CC abnormalities of the hypothalamic-pituitary axis. In some cases, it is
CC associated with non-reproductive phenotypes, such as anosmia, cleft
CC palate, and sensorineural hearing loss. Anosmia or hyposmia is related
CC to the absence or hypoplasia of the olfactory bulbs and tracts.
CC Hypogonadism is due to deficiency in gonadotropin-releasing hormone and
CC probably results from a failure of embryonic migration of gonadotropin-
CC releasing hormone-synthesizing neurons. In the presence of anosmia,
CC idiopathic hypogonadotropic hypogonadism is referred to as Kallmann
CC syndrome, whereas in the presence of a normal sense of smell, it has
CC been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).
CC {ECO:0000269|PubMed:23643382}. Note=The disease is caused by variants
CC affecting distinct genetic loci, including the gene represented in this
CC entry. Some patients carrying mutations in IL17RD also have a
CC heterozygous mutation in another HH-associated gene including FGFR1 and
CC KISS1R (PubMed:23643382). {ECO:0000269|PubMed:23643382}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF494208; AAM74077.1; -; mRNA.
DR EMBL; AF494211; AAM74080.1; -; mRNA.
DR EMBL; AY489047; AAS15051.2; -; mRNA.
DR EMBL; AF458067; AAM77571.1; -; mRNA.
DR EMBL; AY358774; AAQ89134.1; -; mRNA.
DR EMBL; AL133097; CAB61408.1; -; mRNA.
DR EMBL; AL833913; CAD38769.1; -; mRNA.
DR EMBL; BC111702; AAI11703.2; -; mRNA.
DR CCDS; CCDS2880.2; -. [Q8NFM7-1]
DR CCDS; CCDS82790.1; -. [Q8NFM7-2]
DR PIR; T42695; T42695.
DR RefSeq; NP_001305793.1; NM_001318864.1. [Q8NFM7-2]
DR RefSeq; NP_060033.3; NM_017563.4. [Q8NFM7-1]
DR RefSeq; XP_006713272.1; XM_006713209.3.
DR RefSeq; XP_011532151.2; XM_011533849.2. [Q8NFM7-2]
DR AlphaFoldDB; Q8NFM7; -.
DR SMR; Q8NFM7; -.
DR BioGRID; 120132; 26.
DR IntAct; Q8NFM7; 6.
DR MINT; Q8NFM7; -.
DR STRING; 9606.ENSP00000296318; -.
DR GlyGen; Q8NFM7; 8 sites.
DR iPTMnet; Q8NFM7; -.
DR PhosphoSitePlus; Q8NFM7; -.
DR BioMuta; IL17RD; -.
DR DMDM; 126302555; -.
DR EPD; Q8NFM7; -.
DR MassIVE; Q8NFM7; -.
DR PaxDb; Q8NFM7; -.
DR PeptideAtlas; Q8NFM7; -.
DR PRIDE; Q8NFM7; -.
DR ProteomicsDB; 73324; -. [Q8NFM7-1]
DR ProteomicsDB; 73325; -. [Q8NFM7-2]
DR ProteomicsDB; 73326; -. [Q8NFM7-3]
DR ProteomicsDB; 73327; -. [Q8NFM7-4]
DR Antibodypedia; 31518; 317 antibodies from 31 providers.
DR DNASU; 54756; -.
DR Ensembl; ENST00000296318.12; ENSP00000296318.7; ENSG00000144730.19. [Q8NFM7-1]
DR Ensembl; ENST00000320057.9; ENSP00000322250.5; ENSG00000144730.19. [Q8NFM7-2]
DR Ensembl; ENST00000463523.5; ENSP00000417516.1; ENSG00000144730.19. [Q8NFM7-2]
DR GeneID; 54756; -.
DR KEGG; hsa:54756; -.
DR MANE-Select; ENST00000296318.12; ENSP00000296318.7; NM_017563.5; NP_060033.3.
DR UCSC; uc003dil.3; human. [Q8NFM7-1]
DR CTD; 54756; -.
DR DisGeNET; 54756; -.
DR GeneCards; IL17RD; -.
DR GeneReviews; IL17RD; -.
DR HGNC; HGNC:17616; IL17RD.
DR HPA; ENSG00000144730; Tissue enhanced (choroid).
DR MalaCards; IL17RD; -.
DR MIM; 606807; gene.
DR MIM; 615267; phenotype.
DR neXtProt; NX_Q8NFM7; -.
DR OpenTargets; ENSG00000144730; -.
DR Orphanet; 478; Kallmann syndrome.
DR PharmGKB; PA134993407; -.
DR VEuPathDB; HostDB:ENSG00000144730; -.
DR eggNOG; ENOG502QV61; Eukaryota.
DR GeneTree; ENSGT00940000156669; -.
DR HOGENOM; CLU_024846_0_0_1; -.
DR InParanoid; Q8NFM7; -.
DR OMA; DFCLKAE; -.
DR PhylomeDB; Q8NFM7; -.
DR TreeFam; TF329644; -.
DR PathwayCommons; Q8NFM7; -.
DR Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR SignaLink; Q8NFM7; -.
DR BioGRID-ORCS; 54756; 14 hits in 1068 CRISPR screens.
DR ChiTaRS; IL17RD; human.
DR GenomeRNAi; 54756; -.
DR Pharos; Q8NFM7; Tbio.
DR PRO; PR:Q8NFM7; -.
DR Proteomes; UP000005640; Chromosome 3.
DR RNAct; Q8NFM7; protein.
DR Bgee; ENSG00000144730; Expressed in secondary oocyte and 171 other tissues.
DR ExpressionAtlas; Q8NFM7; baseline and differential.
DR Genevisible; Q8NFM7; HS.
DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR GO; GO:0030368; F:interleukin-17 receptor activity; IBA:GO_Central.
DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; ISS:UniProtKB.
DR GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR InterPro; IPR039465; IL-17_rcpt-like.
DR InterPro; IPR031951; IL17R_D_N.
DR InterPro; IPR013568; SEFIR_dom.
DR InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR PANTHER; PTHR15583; PTHR15583; 1.
DR Pfam; PF16742; IL17R_D_N; 1.
DR Pfam; PF08357; SEFIR; 1.
DR SUPFAM; SSF52200; SSF52200; 1.
DR PROSITE; PS51534; SEFIR; 1.
PE 1: Evidence at protein level;
KW Alternative splicing; Cell membrane; Cytoplasm; Disease variant;
KW Glycoprotein; Golgi apparatus; Hypogonadotropic hypogonadism;
KW Kallmann syndrome; Membrane; Receptor; Reference proteome; Signal;
KW Transmembrane; Transmembrane helix.
FT SIGNAL 1..16
FT /evidence="ECO:0000255"
FT CHAIN 17..739
FT /note="Interleukin-17 receptor D"
FT /id="PRO_0000041871"
FT TOPO_DOM 17..299
FT /note="Extracellular"
FT /evidence="ECO:0000255"
FT TRANSMEM 300..320
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 321..739
FT /note="Cytoplasmic"
FT /evidence="ECO:0000255"
FT DOMAIN 355..509
FT /note="SEFIR"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00867"
FT REGION 614..635
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 650..719
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 665..702
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT CARBOHYD 19
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 55
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 62
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 80
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 137
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 171
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 206
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT CARBOHYD 277
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
FT VAR_SEQ 1..144
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:12958313,
FT ECO:0000303|PubMed:17974005"
FT /id="VSP_015582"
FT VAR_SEQ 1..42
FT /note="MAPWLQLCSVFFTVNACLNGSQLAVAAGGSGRARGADTCGWR -> MPRASA
FT SGVPALFVSGEQ (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:12975309"
FT /id="VSP_015583"
FT VAR_SEQ 1..42
FT /note="MAPWLQLCSVFFTVNACLNGSQLAVAAGGSGRARGADTCGWR -> MDYRQS
FT WPWQ (in isoform 4)"
FT /evidence="ECO:0000303|PubMed:14742870,
FT ECO:0000303|PubMed:15489334"
FT /id="VSP_015584"
FT VARIANT 131
FT /note="K -> T (in HH18; results in decreased expression at
FT the cell surface and reduced activity; dbSNP:rs184758350)"
FT /evidence="ECO:0000269|PubMed:23643382"
FT /id="VAR_069936"
FT VARIANT 162
FT /note="K -> R (in HH18; results in decreased expression at
FT the cell surface)"
FT /evidence="ECO:0000269|PubMed:23643382"
FT /id="VAR_069937"
FT VARIANT 255
FT /note="T -> M (in dbSNP:rs6780995)"
FT /evidence="ECO:0000269|PubMed:12958313,
FT ECO:0000269|PubMed:12975309, ECO:0000269|PubMed:14742870,
FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005,
FT ECO:0000269|Ref.3"
FT /id="VAR_023478"
FT VARIANT 301
FT /note="V -> M (in dbSNP:rs17057718)"
FT /id="VAR_023479"
FT VARIANT 306
FT /note="P -> S (in HH18; reduced activity)"
FT /evidence="ECO:0000269|PubMed:23643382"
FT /id="VAR_069938"
FT VARIANT 379
FT /note="Y -> C (in HH18; rare variant associated with
FT susceptibility to disease; some patients have a second
FT mutation in the HH-associated gene FGFR1; reduced activity;
FT dbSNP:rs369641068)"
FT /evidence="ECO:0000269|PubMed:23643382"
FT /id="VAR_069939"
FT VARIANT 468
FT /note="S -> L (in HH18; reduced activity;
FT dbSNP:rs145221454)"
FT /evidence="ECO:0000269|PubMed:23643382"
FT /id="VAR_069940"
FT VARIANT 577
FT /note="P -> Q (in HH18; reduced activity;
FT dbSNP:rs587776980)"
FT /evidence="ECO:0000269|PubMed:23643382"
FT /id="VAR_069941"
FT VARIANT 735
FT /note="A -> V (in HH18; rare variant associated with
FT susceptibility to disease; the patient carries a second
FT mutation in the HH-associated gene KISS1R; results in
FT decreased expression at the cell surface;
FT dbSNP:rs587776979)"
FT /evidence="ECO:0000269|PubMed:23643382"
FT /id="VAR_069942"
FT CONFLICT 223
FT /note="H -> HGSDMQVSFDHAPH (in Ref. 4; CAB61408)"
FT /evidence="ECO:0000305"
FT CONFLICT 248
FT /note="K -> E (in Ref. 1; AAM74077)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 739 AA; 82411 MW; 7A2B45818DBD6E44 CRC64;
MAPWLQLCSV FFTVNACLNG SQLAVAAGGS GRARGADTCG WRGVGPASRN SGLYNITFKY
DNCTTYLNPV GKHVIADAQN ITISQYACHD QVAVTILWSP GALGIEFLKG FRVILEELKS
EGRQCQQLIL KDPKQLNSSF KRTGMESQPF LNMKFETDYF VKVVPFPSIK NESNYHPFFF
RTRACDLLLQ PDNLACKPFW KPRNLNISQH GSDMQVSFDH APHNFGFRFF YLHYKLKHEG
PFKRKTCKQE QTTETTSCLL QNVSPGDYII ELVDDTNTTR KVMHYALKPV HSPWAGPIRA
VAITVPLVVI SAFATLFTVM CRKKQQENIY SHLDEESSES STYTAALPRE RLRPRPKVFL
CYSSKDGQNH MNVVQCFAYF LQDFCGCEVA LDLWEDFSLC REGQREWVIQ KIHESQFIIV
VCSKGMKYFV DKKNYKHKGG GRGSGKGELF LVAVSAIAEK LRQAKQSSSA ALSKFIAVYF
DYSCEGDVPG ILDLSTKYRL MDNLPQLCSH LHSRDHGLQE PGQHTRQGSR RNYFRSKSGR
SLYVAICNMH QFIDEEPDWF EKQFVPFHPP PLRYREPVLE KFDSGLVLND VMCKPGPESD
FCLKVEAAVL GATGPADSQH ESQHGGLDQD GEARPALDGS AALQPLLHTV KAGSPSDMPR
DSGIYDSSVP SSELSLPLME GLSTDQTETS SLTESVSSSS GLGEEEPPAL PSKLLSSGSC
KADLGCRSYT DELHAVAPL
